Last Updated on July 21, 2025 by The Health Master
USFDA approval
Pharmaceutical company Lupin Limited has announced that the firm has gotten United States Food and Drug Administration approval (USFDA approval) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, available in 1 mg and 2 mg strengths.
Understanding the Breakthrough
Prucalopride Tablets, the generic equivalent of Takeda Pharmaceuticals U.S.A.’s Motegrity Tablets (1 mg and 2 mg), offer a much-needed alternative in the landscape of chronic constipation management.
Chronic idiopathic constipation is a widespread and often distressing condition characterized by infrequent and difficult bowel movements, significant abdominal discomfort, and a negative impact on quality of life, without an identifiable underlying cause.
Q: What is meant by Chronic Idiopathic Constipation (CIC)?
A: Chronic Idiopathic Constipation (CIC) is a condition defined by infrequent and difficult bowel movements, hard stools, and a feeling of incomplete evacuation, without an identifiable underlying medical cause or structural abnormality.
Disclaimer: This article contains information obtained from the source mentioned below. Our team made changes in the format to rewrite and present the news or article in a unique format.
Disclaimer: The information we have provided is for general knowledge and for informational purpose only and it cannot be treated as medical advice. Always consult your doctor for any health issues and / or for the treatment of the same. The Health Master does not claim responsibility for this information.
USFDA approval granted for Amlodipine & Atorvastatin Tablets USP
USFDA approval granted for Raltegravir Tablets
USFDA approval granted for generic Hypertension drug
USFDA approval granted for Rivaroxaban tablets
Tentative USFDA approval granted for Amifampridine Tablets
USFDA approval granted for Methenamine Hippurate Tablets: Zydus
USFDA inspection: At Unichem with 3 observations: Roha
USFDA inspection: At Natco Pharma with 7 observations: Hyderabad
FSSAI: Food Labelling and Display – Chapter-19
Role of pharmacist in Healthcare system
Counterfeit Cholesterol Drugs Seized in Hyderabad: DCA Telangana
Drug alert: 186 drug samples declared as NSQ in May 2025
Key Notes on Revised Schedule M: API Part-6
USFDA inspection: At Sun Pharma with 8 observations: Halol
